Co-targeting Nectin4-positive tumor cells and FAP-positive CAFs using Nectin4-7.19 CAR-T cell treatment and FAP-12 CAR-T cell therapy will be a promising synergistic strategy [29]. This evidence concerns the gene NECTIN4 and neoplasm.